Kalaris Therapeutics, Inc.

Q: Jun 30 2026

Q: Mar 31 2026

FY: Dec 31 2025

Q: Sep 30 2025

Q: Jun 30 2025

Q: Mar 31 2025

FY: Dec 31 2024

Q: Sep 30 2024

Q: Jun 30 2024

Q: Mar 31 2024

FY: Dec 31 2023

Q: Sep 30 2023

Q: Jun 30 2023

Q: Mar 31 2023

FY: Dec 31 2022

Q: Sep 30 2022

Q: Jun 30 2022

Q: Mar 31 2022

FY: Dec 31 2021

FY: Dec 31 2021

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Regulation FD Disclosure

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Results of Operations and Financial Condition

Regulation FD Disclosure

Entry into a Material Definitive Agreement

Regulation FD Disclosure

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Shareholder Nominations Pursuant to Exchange Act Rule 14a-11

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Completion of Acquisition or Disposition of Assets

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Notice of Effectiveness

Registration statement under Securities Act of 1933

Registration statement under Securities Act of 1933

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 (amendment)

Registration statement under Securities Act of 1933 (amendment)

Written communication about a business combination transaction (Rule 425)

Written communication about a business combination transaction (Rule 425)

Written communication about a business combination transaction (Rule 425)

Written communication about a business combination transaction (Rule 425)

Written communication about a business combination transaction (Rule 425)

Registration statement under Securities Act of 1933

Written communication about a business combination transaction (Rule 425)

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Vandekop Amy O'Leary

KEATING LAURIE

KEATING LAURIE

Vandekop Amy O'Leary

Bayko Liisa Ann

Bayko Liisa Ann

PATTERSON LEONE D

Jovan-Embiricos Morana

Ferrara Napoleone

Hallal David

AKKARAJU SRINIVAS

Dybbs Michael

ADAMIS ANTHONY P

Samsara BioCapital, L.P.

AKKARAJU SRINIVAS; Samsara BioCapital, L.P.; Samsara Opportunity Fund GP, LLC; Samsara BioCapital GP, LLC; Samsara Opportunity Fund, L.P.

Hagen Brett R

Gall Matthew

Feinsod Matthew

Oxtoby Andrew

Hagen Brett R

Annual Report Scanned (Paper)

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Letter from the SEC

Annual Report Scanned (Paper)

No description available

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

No description available

Letter from the SEC

Annual Report Scanned (Paper)

Annual Report Scanned (Paper)

Post-effective amendment to an automatic shelf registration statement

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC